Examples of using Combination with other antiretroviral agents in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
These patients received PREZISTA/ritonavir 800/100 mg once daily in combination with other antiretroviral agents.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients adults and children of 2 years of age and older.
On the basis of current pharmacodynamic data, indinavir must be used in combination with other antiretroviral agents.
Zerit has been studied in combination with other antiretroviral agents, e. g. didanosine, lamivudine, ritonavir, indinavir, saquinavir, efavirenz, and nelfinavir.
The following events have also been reported when VIRAMUNE has been used in combination with other antiretroviral agents.
Therapeutic Indications CRIXIVAN should be used in combination with other antiretroviral agents for the treatment of HIV- 1 infected adult and paediatric patients.
Rare(≥ 0.01%-≤ 0.1%): hepatitis, abnormal liver enzymes andjaundice when nelfinavir is used in combination with other antiretroviral agents.
These patients received PREZISTA/ritonavir twice daily in combination with other antiretroviral agents see section 4.2 for dosage recommendations per body weight.
After 7 days, the recommended dose of Invirase is 1000 mg two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
HIV-1 infection: Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older.
Mg(1 x 500 mg film-coated tablet) two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents for the first 7 days of treatment.
Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor(PI) experienced HIV-1 infected adults and children above the age of 4 years.
However, for the treatment of HIV infection only a 300 mg daily dose of lamivudine(in combination with other antiretroviral agents) has been shown to be efficacious.
The effects of Kaletra(in combination with other antiretroviral agents) on biological markers(plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra of 48 to 360 weeks duration.
Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in combination with other antiretroviral agents.
Clinical pharmacodynamic data:treatment with nelfinavir alone or in combination with other antiretroviral agents has been documented to reduce viral load and increase CD4 cell counts in HIV-1 seropositive patients.
The interaction profile of APTIVUS, co-administered with low dose ritonavir, is complex andrequires special attention in particular in combination with other antiretroviral agents.
In controlled clinical trials conducted world-wide,indinavir was administered alone or in combination with other antiretroviral agents(zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males 15% females.
In three paediatric studies, treatment-naïve(n=123) and treatment-experienced(n=46)paediatric patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents.
Emtricitabine in combination with other antiretroviral agents, including nucleoside analogues, non-nucleoside analogues and protease inhibitors, has been shown to be effective in the treatment of HIV infection in treatment-naïve patients and treatment-experienced patients with stable virological control.
Raltegravir has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to less than 2 years of age, in combination with other antiretroviral agents in IMPAACT P1066 see sections 5.1 and 5.2.
In combination with ritonavir The recommended dose of Invirase is 1000 mg(5 x 200 mg capsules)two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Children(4 to 12 years) and patients less than 50 kg body weight:the recommended dose of Agenerase capsules is 20 mg/kg body weight twice a day, in combination with other antiretroviral agents, without exceeding a total daily dose of 2400 mg see section 5.1.
The Committee for Medicinal Products for Human Use(CHMP)decided that Emtriva' s benefits are greater than its risks for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.
For treatment-naïve patients initiating treatment with Invirase/ritonavir, the recommended starting dose of Invirase is 500 mg(1 x 500 mg film-coated tablet)two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents for the first 7 days of treatment see Summary of Product Characteristics for INVIRASE 500 mg film-coated tablets.
In combination with ritonavir The recommended dose of Invirase is 1000 mg(2 x 500 mg film-coated tablets)two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Two studies have compared the safety and efficacy of nelfinavir(unboosted)with ritonavir- boosted protease inhibitors, each in combination with other antiretroviral agents.
Adults and adolescents of 12 years of age and older(greater than 50 kg body weight): the recommended dose of Agenerasecapsules is 600 mg twice daily with ritonavir, 100 mg twice daily, in combination with other antiretroviral agents.
The Committee for Medicinal Products for Human Use(CHMP) decided that Kaletra' s benefits are greater than its risks forthe treatment of HIV-1 infected adults and children above the age of two years, in combination with other antiretroviral agents.
ART-naïve HIV-1 infected paediatric patients aged from 12 to 17 years andweighing at least 40 kg who received PREZISTA tablets with low dose ritonavir once daily in combination with other antiretroviral agents see section 5.1.